Filing Summary
Registrant and period: The April 20, 2023 Form 8-K was filed by Vallon Pharmaceuticals, Inc. (Nasdaq: VLON), not by GRI Bio, Inc. The filing reports results of a virtual special meeting of stockholders held on April 20, 2023, relating primarily to the proposed merger with GRI Bio, Inc.
Business Context and Reporting Period
As of the March 6, 2023 record date, Vallon had 13,482,342 common shares outstanding and entitled to vote. A total of 9,003,182 shares, approximately 67%, were present in person or by proxy, constituting a quorum.
Key Financial and Capitalization Information
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
- Stockholders approved the issuance of common shares in connection with the proposed merger, equity financing, and Series T warrant exercises. The issuance is expected to represent more than 20% of the shares outstanding immediately before those transactions.
- Stockholders approved a reverse stock split in a range of 1-for-15 to 1-for-40, with the final ratio to be mutually agreed upon by Vallon and the investor before the merger becomes effective.
- Stockholders approved an amended and restated 2018 Equity Incentive Plan increasing the aggregate shares available for issuance to 6,500,000.
Material Changes and Voting Results
| Proposal | Result | Votes For | Votes Against | Abstained | Broker Non-Votes |
|---|---|---|---|---|---|
| Merger-related share issuance and change of control | Approved | 6,094,211 | 458,506 | 134,434 | 2,316,031 |
| Reverse stock split authorization | Approved | 8,074,479 | 739,775 | 188,928 | — |
| Officer liability limitation | Not approved | 5,622,534 | 825,784 | 238,833 | 2,316,031 |
| Amended and restated 2018 Equity Incentive Plan | Approved | 5,744,077 | 866,498 | 76,576 | 2,316,031 |
| Meeting postponement or adjournment | Approved | 5,961,827 | 636,420 | 88,904 | 2,316,031 |
Outlook, Risks, Contingencies, and Unusual Items
- The approvals support the proposed merger, related equity financing, Series T warrant exercises, and a potential change of control, but this filing does not state that the merger had closed.
- The reverse split ratio remained undetermined within the approved 1-for-15 to 1-for-40 range as of the filing date.
- The anticipated issuance of more than 20% of pre-transaction shares and the change of control may result in substantial dilution and ownership changes for existing stockholders.
- The filing contains no financial guidance or management forecast.
Important Facts to Verify
- Confirm the final closing date and terms of the Vallon–GRI Bio merger.
- Verify the final reverse stock split ratio and effective date.
- Review the definitive equity financing and Series T warrant exercise terms, including resulting dilution.
- Confirm the post-transaction capitalization, ownership structure, Nasdaq compliance, and available cash.
- Review Exhibit 99.1 and subsequent SEC filings for updates not included in this Form 8-K.